IMCR (Immunocore Holdings) Research & Development : $222.2 Mil (TTM As of Dec. 2024)

View and export this data going back to 2021. Start your Free Trial

What is Immunocore Holdings Research & Development?

Research & Development is the aggregate amount of research and development expenses during the year. Immunocore Holdings's Research & Development for the three months ended in Dec. 2024 was $60.9 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Dec. 2024 was $222.2 Mil.

Immunocore Holdings Research & Development Historical Data

The historical data trend for Immunocore Holdings's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Immunocore Holdings Research & Development Chart

Immunocore Holdings Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Research & Development

Get a 7-Day Free Trial

101.95

100.25

101.92

163.55

222.15

Immunocore Holdings Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
Research & Development	Get a 7-Day Free Trial															45.57	57.46	51.07	52.77	60.85

Immunocore Holdings Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $222.2 Mil.

Immunocore Holdings (NAS:IMCR) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

Immunocore Holdings Research & Development Related Terms

Thank you for viewing the detailed overview of Immunocore Holdings's Research & Development provided by GuruFocus.com. Please click on the following links to see related term pages.

Immunocore Holdings Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Immunocore Holdings PLC (NAS:IMCR) » Definitions » Research & Development

Comparable Companies

Traded in Other Exchanges

6YG:Germany

Address

92 Park Drive, Milton Park, Abingdon, Oxfordshire, GBR, OX14 4RY

Website

https://www.immunocore.com

Immunocore Holdings PLC is a commercial-stage biotechnology company. Using its ImmTAX platform, the company is developing a deep pipeline in multiple therapeutic areas, including clinical stage programs in oncology and infectious disease, pre-clinical programs in autoimmune disease, and earlier pre-clinical programs across three therapeutic areas. The company's main product, KIMMTRAK, is used for the treatment of unresectable or metastatic uveal melanoma (mUM). The other drug candidates in its pipeline include Brenetafusp, IMC-P115C, IMC-T119C, IMC-R117C, IMC-S118AI, IMC-U120AI, and others, being developed as a potential treatment for various oncology, infectious, and autoimmune diseases.